Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after repeated vaccine administration. In this study, the subjects previously enrolled in study 104887 will receive a dose with the 2007-2008 season's formulations of Fluarix or GSK576389A. Only subjects who were previously enrolled in study 104887 are eligible for participation in this study.
This study is a year 2 revaccination study. First year revaccination was done in study 104887 (NCT00386698). Primary study was study 104886 (NCT00318149). This study involves 2 age groups (based on primary study):
Subjects enrolled in the ≥ 65 years age group in the primary study. Subjects enrolled in the 18-40 years age group in the primary study.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Adjuvanted influenza vaccine GSK576389A Group | Experimental | Subjects aged ≥ 66 years who previously received 1 dose of adjuvanted influenza vaccine GSK576389A in NCT00318149 and NCT00386698 studies were administered 1 dose of adjuvanted influenza vaccine GSK576389A. |
|
| Fluarix young Group | Active Comparator | Subjects aged 19-42 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine. |
|
| Fluarix elderly Group | Active Comparator | Subjects aged ≥ 66 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fluarix™ | Biological | Single dose, Intramuscular injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis, redness and swelling was greater than 100 millimeter i.e. >100 mm and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade. | Day 0-6 |
| Duration of Solicited Local AEs | Duration was defined as number of days with any grade of local symptoms. | Day 0-6 |
| Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any temperature was defined as axillary temperature ≥38.0 degree centigrade (°C), grade 3 temperature was axillary temperature ≥39.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as general symptom that prevented normal activity. Related was general symptom assessed by the investigator as causally related to the study vaccination. | Day 0-6 |
| Duration of Solicited General AEs | Duration was defined as number of days with any grade of general symptoms. | Day 0-6 |
| Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was event that prevented normal activities and related was defined as unsolicited AE assessed by the investigator to be causally related to the study vaccination. | Day 0-20 |
| Measure | Description | Time Frame |
|---|---|---|
| Haemagglutination Inhibition (HI) Antibody Titers | Antibody titers were expressed as Geometric mean titers (GMTs). The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | At Days 0 and 21 |
| The Number of Subjects Seropositive to HI Antibodies |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | GlaxoSmithKline | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GSK Investigational Site | Ghent | 9000 | Belgium |
Not provided
| Label | URL |
|---|---|
| Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research. | View source |
| ID | Type | URL | Comment |
|---|---|---|---|
| 110263 | Dataset Specification | View IPD |
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Adjuvanted Influenza Vaccine GSK576389A Group | Subjects aged ≥ 66 years who previously received 1 dose of adjuvanted influenza vaccine GSK576389A in NCT00318149 and NCT00386698 studies were administered 1 dose of adjuvanted influenza vaccine GSK576389A. |
| FG001 | Fluarix Elderly Group | Subjects aged ≥ 66 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine. |
| FG002 | Fluarix Young Group | Subjects aged 19-42 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Adjuvanted Influenza Vaccine GSK576389A Group | Subjects aged ≥ 66 years who previously received 1 dose of adjuvanted influenza vaccine GSK576389A in NCT00318149 and NCT00386698 studies were administered 1 dose of adjuvanted influenza vaccine GSK576389A. |
| BG001 | Fluarix Elderly Group |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis, redness and swelling was greater than 100 millimeter i.e. >100 mm and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade. | The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented. | Posted | Number | subjects | Day 0-6 |
|
Serious adverse events were assessed up to day 21. Systematically assessed frequent adverse events (AEs) and Non-systematically assessed frequent AEs were assessed during 7 day and 21 day post-vaccination period respectively.
For the frequent adverse events, the number of participants at risk included those from Total Vaccinated Cohort who had the symptom sheet completed.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Adjuvanted Influenza Vaccine GSK576389A Group | Subjects aged ≥ 66 years who previously received 1 dose of adjuvanted influenza vaccine GSK576389A in NCT00318149 and NCT00386698 studies were administered 1 dose of adjuvanted influenza vaccine GSK576389A. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pain | General disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| GSK Response Center | GlaxoSmithKline | 866-435-7343 |
Not provided
| ID | Term |
|---|---|
| D007251 | Influenza, Human |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D009976 | Orthomyxoviridae Infections |
| D012327 | RNA Virus Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C510903 | fluarix |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| GSK Bio's Influenza Vaccine GSK576389A | Biological | Single dose, Intramuscular injection |
|
| Number of Subjects Reporting at Least One, Grade 3 and Related Medically Significant Conditions (MSCs) | MSCs were defined as AEs with a medically-attended visit i.e. prompting emergency room (ER) visits, hospitalizations or physician visits and that were not routine visits for physical examination or vaccination. At least one MSC was defined as at least one MSC experienced. Grade 3 was MSC that prevented normal activities and Related was defined as MSC assessed by the investigator to be causally related to the study vaccination. | Day 0-20 |
| Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination. | Day 0-20 |
Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e. ≥ 1:10. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
| At Days 0 and 21 |
| The Number of Subjects Seroconverted to HI Antibodies | Seroconversion was defined as either a pre-vaccination titer <1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | At Day 21 |
| HI Antibody Seroconversion Factors (SCF) | SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | At Day 21 |
| The Number of Subjects Seroprotected to HI Antibodies | Seroprotection was defined as serum HI titer ≥1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | At Days 0 and 21 |
| The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | The vaccine strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and Pool FLU antigens and the markers assessed were Cluster of Differentiation 4-All doubles i.e. CD4-All doubles, CD40 Ligand (CD40L), interferon-gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-α). | At Days 0 and 21 |
| The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | The vaccine strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and Pool FLU antigens and the markers assessed were CD8-All doubles, CD40L, IFN-γ, IL-2 and TNF-α. | At Days 0 and 21 |
For additional information about this study please refer to the GSK Clinical Study Register |
| 110263 | Clinical Study Report | View IPD | For additional information about this study please refer to the GSK Clinical Study Register |
| 110263 | Annotated Case Report Form | View IPD | For additional information about this study please refer to the GSK Clinical Study Register |
| 110263 | Statistical Analysis Plan | View IPD | For additional information about this study please refer to the GSK Clinical Study Register |
| 110263 | Individual Participant Data Set | View IPD | For additional information about this study please refer to the GSK Clinical Study Register |
| 110263 | Informed Consent Form | View IPD | For additional information about this study please refer to the GSK Clinical Study Register |
| 110263 | Study Protocol | View IPD | For additional information about this study please refer to the GSK Clinical Study Register |
Subjects aged ≥ 66 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine. |
| BG002 | Fluarix Young Group | Subjects aged 19-42 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine. |
| BG003 | Total | Total of all reporting groups |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Fluarix Elderly Group |
Subjects aged ≥ 66 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine. |
| OG002 | Fluarix Young Group | Subjects aged 19-42 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine. |
|
|
| Primary | Duration of Solicited Local AEs | Duration was defined as number of days with any grade of local symptoms. | The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom. | Posted | Median | Full Range | Days | Day 0-6 |
|
|
|
| Primary | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any temperature was defined as axillary temperature ≥38.0 degree centigrade (°C), grade 3 temperature was axillary temperature ≥39.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as general symptom that prevented normal activity. Related was general symptom assessed by the investigator as causally related to the study vaccination. | The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented. | Posted | Number | subjects | Day 0-6 |
|
|
|
| Primary | Duration of Solicited General AEs | Duration was defined as number of days with any grade of general symptoms. | The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom. | Posted | Median | Full Range | Days | Day 0-6 |
|
|
|
| Primary | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was event that prevented normal activities and related was defined as unsolicited AE assessed by the investigator to be causally related to the study vaccination. | The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented. | Posted | Number | subjects | Day 0-20 |
|
|
|
| Primary | Number of Subjects Reporting at Least One, Grade 3 and Related Medically Significant Conditions (MSCs) | MSCs were defined as AEs with a medically-attended visit i.e. prompting emergency room (ER) visits, hospitalizations or physician visits and that were not routine visits for physical examination or vaccination. At least one MSC was defined as at least one MSC experienced. Grade 3 was MSC that prevented normal activities and Related was defined as MSC assessed by the investigator to be causally related to the study vaccination. | The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented. | Posted | Number | subjects | Day 0-20 |
|
|
|
| Primary | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination. | The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented. | Posted | Number | subjects | Day 0-20 |
|
|
|
| Secondary | Haemagglutination Inhibition (HI) Antibody Titers | Antibody titers were expressed as Geometric mean titers (GMTs). The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity were available at day 21. | Posted | Geometric Mean | 95% Confidence Interval | titer | At Days 0 and 21 |
|
|
|
| Secondary | The Number of Subjects Seropositive to HI Antibodies | Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e. ≥ 1:10. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity were available at day 21. | Posted | Number | subjects | At Days 0 and 21 |
|
|
|
| Secondary | The Number of Subjects Seroconverted to HI Antibodies | Seroconversion was defined as either a pre-vaccination titer <1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity were available at day 21. | Posted | Number | subjects | At Day 21 |
|
|
|
| Secondary | HI Antibody Seroconversion Factors (SCF) | SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity were available at day 21. | Posted | Geometric Mean | 95% Confidence Interval | fold increase | At Day 21 |
|
|
|
| Secondary | The Number of Subjects Seroprotected to HI Antibodies | Seroprotection was defined as serum HI titer ≥1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. | Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity were available at day 21. | Posted | Number | subjects | At Days 0 and 21 |
|
|
|
| Secondary | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | The vaccine strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and Pool FLU antigens and the markers assessed were Cluster of Differentiation 4-All doubles i.e. CD4-All doubles, CD40 Ligand (CD40L), interferon-gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-α). | Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity were available at day 21. | Posted | Geometric Mean | Standard Deviation | CD4 cells/10^6 CD4+ cells | At Days 0 and 21 |
|
|
|
| Secondary | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | The vaccine strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and Pool FLU antigens and the markers assessed were CD8-All doubles, CD40L, IFN-γ, IL-2 and TNF-α. | Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity were available at day 21. | Posted | Geometric Mean | Standard Deviation | CD8 cells/10^6 CD8+ cells | At Days 0 and 21 |
|
|
|
| 0 |
| 55 |
| 46 |
| 55 |
| EG001 | Fluarix Elderly Group | Subjects aged ≥ 66 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine. | 0 | 40 | 24 | 40 |
| EG002 | Fluarix Young Group | Subjects aged 19-42 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine. | 0 | 38 | 36 | 38 |
| Redness | General disorders | Systematic Assessment |
|
| Swelling | General disorders | Systematic Assessment |
|
| Arthralgia | General disorders | Systematic Assessment |
|
| Fatigue | General disorders | Systematic Assessment |
|
| Headache | General disorders | Systematic Assessment |
|
| Myalgia | General disorders | Systematic Assessment |
|
| Nausea | General disorders | Systematic Assessment |
|
| Shivering | General disorders | Systematic Assessment |
|
| Temperature | General disorders | Systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | Non-systematic Assessment |
|
| Pharyngolaryngeal pain | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
|
| Rhinitis | Infections and infestations | Non-systematic Assessment |
|
| Gastroenteritis | Infections and infestations | Non-systematic Assessment |
|
| Headache | Nervous system disorders | Non-systematic Assessment |
|
| Influenza like illness | General disorders | Non-systematic Assessment |
|
| Injection site pruritus | General disorders | Non-systematic Assessment |
|
GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
| D014777 | Virus Diseases |
| D012140 | Respiratory Tract Diseases |
|
| Swelling (N=6; 4; 0) |
|
| Title | Measurements |
|---|---|
|
| Related arthralgia |
|
| Any fatigue |
|
| Grade 3 fatigue |
|
| Related fatigue |
|
| Any headache |
|
| Grade 3 headache |
|
| Related headache |
|
| Any myalgia |
|
| Grade 3 myalgia |
|
| Related myalgia |
|
| Any nausea |
|
| Grade 3 nausea |
|
| Related nausea |
|
| Any shivering |
|
| Grade 3 shivering |
|
| Related shivering |
|
| Any temperature |
|
| Grade 3 temperature |
|
| Related temperature |
|
|
| Headache (N=13; 5; 8) |
|
| Myalgia (N=10; 3; 10) |
|
| Nausea (N=4; 0; 3) |
|
| Shivering (N=10; 0; 2) |
|
| Temperature (N=4; 0; 0) |
|
| Title | Measurements |
|---|---|
|
| Related AE(s) |
|
| Title | Measurements |
|---|---|
|
| Related MSC |
|
| Title | Measurements |
|---|---|
|
| A/Solomon Islands strain at Day 21 (N=51; 39; 38) |
|
| A/Wisconsin strain at Day 0 (N=52; 39; 38) |
|
| A/Wisconsin strain at Day 21 (N=51; 39; 38) |
|
| B/Malaysia strain at Day 0 (N=52; 39; 38) |
|
| B/Malaysia strain at Day 21 (N=51; 39; 38) |
|
|
| A/Wisconsin strain at Day 0 (N=52; 39; 38) |
|
| A/Wisconsin strain at Day 21 (N=51; 39; 38) |
|
| B/Malaysia strain at Day 0 (N=52; 39; 38) |
|
| B/Malaysia strain at Day 21 (N=51; 39; 38) |
|
|
| B/Malaysia strain |
|
|
| B/Malaysia strain |
|
|
| A/Wisconsin strain at Day 0 (N= 52; 39; 38) |
|
| A/Wisconsin strain at Day 21 (N= 51; 39; 38) |
|
| B/Malaysia strain at Day 0 (N=52; 39; 38) |
|
| B/Malaysia strain at Day 21 (N=51; 39; 38) |
|
|
| A/Wisconsin[CD4-All doubles] D0 (N=44;36;36) |
|
| A/Wisconsin[CD4-All doubles] D21 (N=44;36;35) |
|
| B/Malaysia[CD4-All doubles] D0 (N=44;35;36) |
|
| B/Malaysia[CD4-All doubles] D21 (N=44;36;35) |
|
| Pool FLU[CD4-All doubles] D0 (N=44;36;36) |
|
| Pool FLU[CD4-All doubles] D21 (N=44;36;35) |
|
| A/Solomon Islands[CD4-CD40L] D0 (N=44;36;36) |
|
| A/Solomon Islands[CD4-CD40L] D21(N=44;36;35) |
|
| A/Wisconsin[CD4-CD40L] D0 (N=44;36;36) |
|
| A/Wisconsin[CD4-CD40L] D21 (N=44;36;35) |
|
| B/Malaysia[CD4-CD40L] D0 (N=44;35;36) |
|
| B/Malaysia[CD4-CD40L] D21 (N=44;36;35) |
|
| Pool FLU[CD4-CD40L] D0 (N=44;36;36) |
|
| Pool FLU[CD4-CD40L] D0 (N=44;36;35) |
|
| A/Solomon Islands[CD4-IFNγ] D0 (N=44;36;36) |
|
| A/Solomon Islands[CD4-IFNγ] D21 (N=44;36;35) |
|
| A/Wisconsin[CD4-IFNγ] D0 (N=44;36;36) |
|
| A/Wisconsin[CD4-IFNγ] D21 (N=44;36;35) |
|
| B/Malaysia[CD4-IFNγ] D0 (N=44;35;36) |
|
| B/Malaysia[CD4-IFNγ] D21 (N=44;36;35) |
|
| Pool FLU[CD4-IFNγ] D0 (N=44;36;36) |
|
| Pool FLU[CD4-IFNγ] D21 (N=44;36;35) |
|
| A/Solomon Islands[CD4-IL2] D0 (N=44;36;36) |
|
| A/Solomon Islands[CD4-IL2] D21 (N=44;36;35) |
|
| A/Wisconsin[CD4-IL2] D0 (N=44;36;36) |
|
| A/Wisconsin[CD4-IL2] D21 (N=44;36;35) |
|
| B/Malaysia[CD4- IL2] D0 (N=44;35;36) |
|
| B/Malaysia[CD4- IL2] D21 (N=44;36;35) |
|
| Pool FLU[CD4-IL2] D0 (N=44;36;36) |
|
| Pool FLU[CD4-IL2] D21 (N=44;36;35) |
|
| A/Solomon Islands[CD4-TFNα] D0 (N=44;36;36) |
|
| A/Solomon Islands[CD4-TFNα] D21 (N=44;36;35) |
|
| A/Wisconsin[CD4-TFNα] D0 (N=44;36;36) |
|
| A/Wisconsin[CD4-TFNα] D21 (N=44;36;35) |
|
| B/Malaysia[CD4- TFNα] D0 (N=44;35;36) |
|
| B/Malaysia[CD4- TFNα] D21 (N=44;36;35) |
|
| Pool FLU[CD4-TFNα] D0 (N=44;36;36) |
|
| Pool FLU[CD4-TFNα] D21 (N=44;36;35) |
|
|
| A/Wisconsin[CD8-All doubles] D0 (N=43;36;36) |
|
| A/Wisconsin[CD8-All doubles] D21 (N=44;36;35) |
|
| B/Malaysia[CD8-All doubles] D0 (N=44;35;36) |
|
| B/Malaysia[CD8-All doubles] D21 (N=44;36;35) |
|
| Pool FLU[CD8-All doubles] D0 (N=44;36;36) |
|
| Pool FLU[CD8-All doubles] D21 (N=44;36;35) |
|
| A/Solomon Islands[CD8-CD40L] D0 (N=44;36;36) |
|
| A/Solomon Islands[CD8-CD40L] D21 (N=44;36;35) |
|
| A/Wisconsin[CD8-CD40L] D0 (N=43;36;36) |
|
| A/Wisconsin[CD8-CD40L] D21 (N=44;36;35) |
|
| B/Malaysia[CD8-CD40L] D0 (N=44;35;36) |
|
| B/Malaysia[CD8-CD40L] D21 (N=44;36;35) |
|
| Pool FLU[CD8-CD40L] D0 (N=44;36;36) |
|
| Pool FLU[CD8-CD40L] D21 (N=44;36;35) |
|
| A/Solomon Islands[CD8-IFNγ] D0 (N=44;36;36) |
|
| A/Solomon Islands[CD8-IFNγ] D21 (N=44;36;35) |
|
| A/Wisconsin[CD8-IFNγ] D0 (N=43;36;36) |
|
| A/Wisconsin[CD8-IFNγ] D21 (N=44;36;35) |
|
| B/Malaysia[CD8-IFNγ] D0 (N=44;35;36) |
|
| B/Malaysia[CD8-IFNγ] D21 (N=44;36;35) |
|
| Pool FLU[CD8-IFNγ] D0 (N=44;36;36) |
|
| Pool FLU[CD8-IFNγ] D21 (N=44;36;35) |
|
| A/Solomon Islands[CD8-IL2] D0 (N=44;36;36) |
|
| A/Solomon Islands[CD8-IL2] D21 (N=44;36;35) |
|
| A/Wisconsin[CD8-IL2] D0 (N=43;36;36) |
|
| A/Wisconsin[CD8-IL2] D21 (N=44;36;35) |
|
| B/Malaysia[CD8-IL2] D0 (N=44;35;36) |
|
| B/Malaysia[CD8-IL2] D21 (N=44;36;35) |
|
| Pool FLU[CD8-IL2] D0 (N=44;36;36) |
|
| Pool FLU[CD8-IL2] D21 (N=44;36;35) |
|
| A/Solomon Islands[CD8-TFNα] D0 (N=44;36;36) |
|
| A/Solomon Islands[CD8-TFNα] D21 (N=44;36;35) |
|
| A/Wisconsin[CD8-TFNα] D0 (N=43;36;36) |
|
| A/Wisconsin[CD8-TFNα] D21 (N=44;36;35) |
|
| B/Malaysia[CD8-TFNα] D0 (N=44;35;36) |
|
| B/Malaysia[CD8-TFNα] D21 (N=44;36;35) |
|
| Pool FLU[CD8-TFNα] D0 (N=44;36;36) |
|
| Pool FLU[CD8-TFNα] D21 (N=44;36;35) |
|